# EDGAR Filing Document

**Accession Number:** 0001842952
**File Stem:** 0001628280-25-046258
**Filing Date:** 2025-10
**Character Count:** 26434
**Document Hash:** e05788484db809f1281985b8c5505747
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-046258.hdr.sgml**: 20251024

**ACCESSION NUMBER**: 0001628280-25-046258

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20251024

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251024

**DATE AS OF CHANGE**: 20251024

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Context Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001842952
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 863738787
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40654
- **FILM NUMBER:** 251416142

**BUSINESS ADDRESS:**
- **STREET 1:** 2001 MARKET STREET
- **STREET 2:** SUITE 3915 UNIT #15
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19103
- **BUSINESS PHONE:** 267-225-7416

**MAIL ADDRESS:**
- **STREET 1:** 2001 MARKET STREET
- **STREET 2:** SUITE 3915 UNIT #15
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19103

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Context Therapeutics LLC
- **DATE OF NAME CHANGE:** 20210128

?xml version='1.0' encoding='ASCII'? cntx-20251024

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 24, 2025**

**Context Therapeutics Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40654** | **86-3738787** |
| **(State of other jurisdiction of incorporation)** | **(Commission File Number)** | **(I.R.S. Employer Identification No.)** |

---

**2001 Market Street, Suite 3915, Unit #15**

**Philadelphia, Pennsylvania 19103**

**(Address of principal executive offices including zip code)**

**(267) 225-7416**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ &nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ &nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ &nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading <br>Symbol** | **Name of exchange<br>on which registered** |
| **Common Stock** | **CNTX** | **The Nasdaq Stock Market** |
| **$0.001 par value per share** |  |  |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 1.01 Entry into a Material Definitive Agreement.**

As previously disclosed, Context Therapeutics Inc. (the "Company") entered into a Sales Agreement (the "Sales Agreement"), dated December 2, 2024, with Leerink Partners LLC (the "Agent"). Pursuant to the terms of the Sales Agreement, the Company could offer and sell shares of the Company's common stock, $0.001 par value per share (the "Shares"), having an aggregate offering amount of up to $75.0 million from time to time through the Agent under a shelf registration statement on Form S-3 (File No. 333-268266), including the related prospectus, that was filed with the Securities and Exchange Commission (the "SEC), and declared effective on November 16, 2022, as supplemented by a prospectus supplement dated December 2, 2024 (the "Prior ATM Sales Prospectus"). As of October 24, 2025, the Company had offered and sold 14,705,882 Shares under the Prior ATM Sales Prospectus at an aggregate offering price of approximately $15.0 million.

On October 24, 2025, the Company entered into Amendment No. 1 to Sales Agreement (the "Amendment", and together with the Sales Agreement, the "Amended Sales Agreement") to provide for an increase in the aggregate offering amount under the Amended Sales Agreement, such that as of October 24, 2025, the Company may offer and sell Shares having an aggregate offering price of up to $75.0 million, exclusive of Shares previously sold pursuant to the Prior ATM Sales Prospectus. In addition, the Amendment provides for the offer and sale of Shares pursuant to the Company's registration statement on Form S-3 (File No. 333-283037), including the related prospectus, that was filed with the SEC, and declared effective on November 14, 2024, as supplemented by a prospectus supplement dated October 24, 2025. The material terms and conditions of the Sales Agreement otherwise remain unchanged.

Sales of the Shares, if any, may be made in sales deemed to be an "at-the-market offering" as defined in Rule 415 under the Securities Act of 1933, as amended. The Agent will use its commercially reasonable efforts, subject to the terms of the Amended Sales Agreement, to sell the Shares offered.

The Agent will be entitled to a commission from the Company of up to 3.0% of the gross proceeds from the sale of Shares sold under the Amended Sales Agreement. In addition, the Company has agreed to reimburse certain expenses incurred by the Agent in connection with the execution of the Amendment. The Company intends to use any net proceeds from the offering for research and development of the Company's product candidates and working capital and general corporate purposes, which may include the acquisition of additional assets.

The Amended Sales Agreement contains customary representations, warranties, and agreements of the Company and the Agent, indemnification rights and obligations of the parties and termination provisions. The Company is not obligated to make any sales of Shares under the Amended Sales Agreement. The Amended Sales Agreement may be terminated by the Agent for cause at any time or by the Company or the Agent for convenience upon 10 days' prior notice.

The foregoing description of the Amended Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the Sales Agreement, which is filed as <u>[Exhib](https://www.sec.gov/Archives/edgar/data/1842952/000162828024049570/exhibit101-8xkforatmdec2024.htm)[it 10.1](https://www.sec.gov/Archives/edgar/data/1842952/000162828024049570/exhibit101-8xkforatmdec2024.htm)</u> to the Current Report on Form 8-K filed with the SEC on December 2, 2024 and incorporated herein by reference, and the Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

A copy of the opinion of Faegre Drinker Biddle & Reath LLP, counsel to the Company, relating to the legality of the Shares is filed as Exhibit 5.1 to this Current Report on Form 8-K.

**Item 8.01 Other Events.**

On October 24, 2025, the Company notified the Agent that it was suspending the use of and terminating the Prior ATM Sales Prospectus, and the Company will not make any further sales of Shares pursuant to the Prior ATM Sales Prospectus.

**Item 9.01. Financial Statements and Exhibits.**

(**d) Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 5.1 | <u>[Opinion of Faegre Drinker Biddle & Reath LLP](exhibit51-8xk.htm)</u> |
| 10.1 | <u>[Amendment No. 1 to Sales Agreement, dated as of October 24, 2025, by and between Context Therapeutics Inc. and Leerink Partners LLC](exhibit101-8xk.htm)</u> |
| 23.1 | <u>[Consent of Faegre Drinker Biddle & Reath LLP (included in Exhibit 5.1 hereto)](exhibit51-8xk.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: October 24, 2025 | **Context Therapeutics Inc.** | **Context Therapeutics Inc.** |
|  | By: | /s/ Martin A. Lehr |
|  |  | Name: Martin A. Lehr |
|  |  | Title: Chief Executive Officer |

---

## Exhibit 5.1

**Exhibit 5.1**

![exhibit51a.jpg](exhibit51a.jpg)

**Faegre Drinker Biddle & Reath LLP**<br>One Logan Square<br>Suite 2000<br>Philadelphia, Pennsylvania 19103<br>+1 215 988 2700 main<br>+1 215 988 2757 fax<br>

October 24, 2025

Context Therapeutics Inc.

2001 Market Street

Suite 3915, Unit #15

Philadelphia, Pennsylvania 19103

Ladies and Gentlemen:

We have acted as counsel to Context Therapeutics Inc., a Delaware corporation (the "Company"), in connection with the preparation and filing of a prospectus supplement dated October 24, 2025 (the "Prospectus Supplement") to the prospectus dated November 14, 2024 (together with the Prospectus Supplement, the "Prospectus"), related to the offering of up to $75,000,000 of common stock, par value $0.001 per share ("Common Stock"), that may be issued and sold (the "Shares") under a Sales Agreement entered into by the Company with Leerink Partners LLC, dated December 2, 2024, as amended on October 24, 2025 (as so amended, the "Sales Agreement"). The Prospectus forms a part of the Company's Registration Statement on Form S-3 (File No. 333-283037) (the "Registration Statement") filed by the Company with the Securities and Exchange Commission (the "Commission") on November 6, 2024 under the Securities Act of 1933, as amended (the "Securities Act").

This opinion letter is being delivered in accordance with the requirements of Item 601(b)(5) of Regulation S-K.

As counsel for the Company, we are familiar with the Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation") and the Amended and Restated Bylaws (the "Bylaws") of the Company, each as amended to the date hereof, and we have reviewed originals, or copies certified or otherwise authenticated to our satisfaction, of (i) the Registration Statement, (ii) the Prospectus, (iii) the Sales Agreement and (iv) the proceedings taken by the Company in connection with the authorization of the Sales Agreement and the Shares. We have also examined originals, or copies certified or otherwise authenticated to our satisfaction, of such corporate records of the Company and other instruments, certificates of public officials and representatives of the Company, and other documents as we have deemed necessary as a basis for the opinion hereinafter expressed and have made such examination of statutes and decisions and reviewed such questions of law as we have considered necessary or appropriate for the purposes of this opinion letter.

Based on and subject to the foregoing and to the other assumptions, qualifications and limitations set forth herein, we are of the opinion that the Shares have been duly authorized and, when (i) the Shares have been issued by the Company against payment of the agreed-upon consideration therefor in accordance with the provisions of the Sales Agreement, and (ii) certificates representing the Shares have been duly executed by the duly authorized officers of the Company, countersigned by the transfer agent therefor and delivered to the purchasers thereof (or in the case of Shares issued without certificates, the due registration of issuance and constructive delivery through book entry of such Shares), then, upon the happening of such events, such Shares will be validly issued, fully paid and non-assessable.

The foregoing opinion assumes that (a) the Registration Statement and any amendments relating thereto will continue to be effective, (b) the Company will remain duly organized, validly existing and in good standing under the laws of the State of Delaware, (c) at the time any Shares are issued, (i) there will not have occurred any change in the law or in the Certificate of Incorporation or Bylaws affecting the issuance of such Shares, and (ii) no relevant corporate actions will have been modified or rescinded, (d) the Shares will be issued within the limits of the then

------

October 24, 2025

remaining authorized but unreserved and unissued amounts of Common Stock under the Certificate of Incorporation, (e) all certificates evidencing any Shares will be in the form required by law and approved for issuance by the Company, (f) the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the General Corporation Law of the State of Delaware, and (g) future issuances of Shares will be made in accordance with the parameters established by the Board of Directors or a Pricing Committee of the Board of Directors, as such parameters may be established from time to time.

We have relied upon certificates of public officials as to the accuracy of all matters addressed therein and, with respect to certain factual matters, upon certificates of and information provided by officers and employees of the Company as to the accuracy of such factual matters, in each case without independent verification thereof or other investigation. We have assumed, without investigation, the following: (a) the genuineness of signatures, including electronic signatures, appearing upon the certifications, documents, and proceedings submitted to us for review, (b) that each document submitted to us for review is accurate and complete, each such document that is an original is authentic and each such document that is a copy conforms to an authentic original, (c) the legal capacity of natural persons who are involved on behalf of the Company to enter into and perform the referenced instrument or agreement or to carry out their role in the transactions contemplated thereby, (d) the truth, accuracy and completeness of the information, representations and warranties contained in the documents, instruments, certificates and records we have reviewed, and (e) the absence of any undisclosed modifications to the agreements and instruments reviewed by us.

Our opinion set forth herein is limited to the General Corporation Law of the State of Delaware, and we express no opinion as to the effect of any other laws.

This opinion letter is rendered as of the date first written above, and we assume no responsibility for updating this opinion letter or the opinion set forth herein to take into account any event, action, interpretation or change in law or facts occurring subsequent to the date hereof that may affect the validity of such opinion. This opinion letter is expressly limited to the matters set forth above, and we render no opinion, whether by implication or otherwise, as to any other matters relating to the Company or the Shares.

We hereby consent to the filing of this opinion letter as an exhibit to the Current Report on Form 8-K of the Company filed with the Commission on the date hereof and to being named in the Prospectus under the caption "Legal Matters" with respect to the matters stated therein without implying or admitting that we are "experts" within the meaning of the Securities Act or other rules and regulations of the Commission promulgated thereunder with respect to any part of the Registration Statement, including this opinion letter.

---

| |
|:---|
| Very truly yours, |
| /s/ Faegre Drinker Biddle & Reath LLP |
| FAEGRE DRINKER BIDDLE & REATH LLP |

---

## Exhibit 10.1

**Exhibit 10.1**

**<u>AMENDMENT NO. 1 TO SALES AGREEMENT</u>** 

October 24, 2025

Leerink Partners LLC

1301 Avenue of the Americas, 5th Floor

New York, New York 10019

Ladies and Gentlemen:

This Amendment No. 1 (this "**<u>Amendment</u>**") to the Sales Agreement, dated December 2, 2024 (the "**<u>Original Agreement</u>**") is entered into as of the date first written above by Context Therapeutics Inc. (the "**<u>Company</u>**") and Leerink Partners LLC (the "**<u>Agent</u>**"). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement.

The parties, intending to be legally bound, hereby amend the Original Agreement as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.The first two paragraphs of Section 1 the Original Agreement are hereby deleted in its entirety and replaced with the following:

"<u>Issuance and Sale of Shares</u>. The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue and sell through the Agent shares of common stock, $0.001 par value per share, of the Company (the "**<u>Common Stock</u>**"), subject to the limitations set forth in Section 5(c) (the "**<u>Placement Shares</u>**"). The issuance and sale of Placement Shares through the Agent will be effected pursuant to the Registration Statement (as defined below) filed by the Company with the Securities and Exchange Commission (the "**<u>Commission</u>**") on November 6, 2024 and declared effective by the Commission on November 14, 2024, although nothing in this Agreement shall be construed as requiring the Company to issue any Placement Shares.

The Company has prepared and filed, in accordance with the provisions of the Securities Act of 1933, as amended, and the rules and regulations thereunder (collectively, the "**<u>Securities Act</u>**"), with the Commission a registration statement on Form S-3 (File No. 333-283037), including a base prospectus, relating to certain securities, including the Common Stock, to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (collectively, the "**<u>Exchange Act</u>**"). The Company has prepared a prospectus supplement to the base prospectus included as part of such registration statement at the time the registration statement became effective, which prospectus supplement specifically relates to the Placement Shares to be issued from time to time pursuant to this Agreement (the "**<u>Prospectus Supplement</u>**"). The Company will furnish to the Agent, for use by the Agent, electronic copies of the base prospectus included as part of such registration statement at the time it became effective, as supplemented by the Prospectus Supplement. The Company may file one or more additional registration statements from time to time that will contain a base prospectus and related prospectus or prospectus supplement, if applicable (which shall be a Prospectus (as defined below)), with respect to the Placement Shares. Except where the context otherwise requires, such registration statement(s), including all documents filed as part thereof or incorporated by reference therein, and including any information contained in a Prospectus subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be a part of such registration statement pursuant to Rule 430B or Rule 462(b)

------

under the Securities Act, is herein called the "**<u>Registration Statement</u>**." The base prospectus, including all documents incorporated therein by reference, included in the Registration Statement, as it may be supplemented by the Prospectus Supplement, in the form in which such prospectus and/or Prospectus Supplement have most recently been filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act, together with any "issuer free writing prospectus" (as used herein, as defined in Rule 433 under the Securities Act ("**<u>Rule 433</u>**")), relating to the Placement Shares that (i) is required to be filed with the Commission by the Company or (ii) is exempt from filing pursuant to Rule 433(d)(5)(i), in each case, in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company's records pursuant to Rule 433(g), is herein called the "**<u>Prospectus</u>**."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Section 11(d) of the Original Agreement is hereby deleted in its entirety and replaced with the following:

"[Reserved.]"

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Except as amended hereby, the Original Agreement as now in effect is ratified and confirmed hereby in all respects.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The representations and warranties of the Company in Section 6 of the Original Agreement, as amended by this Amendment (a) to the extent such representations and warranties are subject to qualifications and exceptions contained therein relating to materiality or Material Adverse Effect, are true and correct on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof, and (b) to the extent such representations and warranties are not subject to any qualifications or exceptions relating to materiality or Material Adverse Effect, are true and correct in all material respects as of the date hereof as if made on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof, except for those representations and warranties that speak solely as of a specific date and which were true and correct as of such date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The Company represents and warrants, and agrees with the Agent that: (a) this Amendment has been duly authorized, executed and delivered by, and is a valid and binding agreement of, the Company, enforceable in accordance with its terms, except as rights to indemnification hereunder may be limited by applicable law and except as the enforcement hereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles; and (b) within two business days of the date hereof, the Company will file the Registration Statement and a Prospectus Supplement with respect to the Placement Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.THIS AMENDMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH PARTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AMENDMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection with any of the transactions contemplated hereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is

------

not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum, or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy (certified or registered mail, return receipt requested) to such party at the address in effect for notices under Section 12 of the Original Agreement, as amended hereby, and agrees that such service shall constitute good and sufficient notice of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed Amendment by one party to the other may be made by facsimile or electronic transmission. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

*[Signature page follows.]* 

------

If the foregoing correctly sets forth the understanding between the Company and the Agent, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between the Company and the Agent.

---

| | | |
|:---|:---|:---|
| Very truly yours, | Very truly yours, | Very truly yours, |
| **LEERINK PARTNERS LLC** | **LEERINK PARTNERS LLC** | **LEERINK PARTNERS LLC** |
| By: | /s/ Peter Fry | /s/ Peter Fry |
|  | Name: | Peter Fry |
|  | Title: | Senior Managing Director, Head of Alternative Equities |

---

[*Signature Page to Amendment No. 1 To Sales Agreement*]

------

---

| | | | |
|:---|:---|:---|:---|
| ACCEPTED as of the date first-above written: |  |  |  |
|  | **CONTEXT THERAPEUTICS INC.** | **CONTEXT THERAPEUTICS INC.** | **CONTEXT THERAPEUTICS INC.** |
|  | By: | /s/ Martin Lehr | /s/ Martin Lehr |
|  |  | Name: | Martin Lehr |
|  |  | Title: | Chief Executive Officer |

---

[*Signature Page to Amendment No. 1 To Sales Agreement*]